Cantor Fitzgerald restated their buy rating on shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) in a research report sent to investors on Thursday, May 11th. The brokerage currently has a $31.00 target price on the biotechnology company’s stock, up from their previous target price of $30.00.
“Expensive 1Q: HRTX reported 1Q17 EPS of ($1.00), below our estimated ($0.83). The difference is mainly attributed to higher than expected R&D spend, though we believe that should taper off through the year, providing some flexibility in cash runway. HRTX finished the quarter with $165M in cash.”,” Cantor Fitzgerald’s analyst wrote.
HRTX has been the subject of several other reports. Zacks Investment Research cut Heron Therapeutics from a hold rating to a strong sell rating in a research report on Tuesday, May 9th. Jefferies Group LLC restated a buy rating and issued a $29.00 price objective on shares of Heron Therapeutics in a research note on Monday, April 10th. Needham & Company LLC assumed coverage on Heron Therapeutics in a research note on Monday, February 27th. They issued a buy rating and a $28.00 price objective on the stock. Finally, Aegis restated a buy rating on shares of Heron Therapeutics in a research note on Tuesday, March 21st. One research analyst has rated the stock with a sell rating and ten have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and a consensus price target of $34.50.
Heron Therapeutics (NASDAQ HRTX) traded up 1.44% during mid-day trading on Thursday, reaching $14.10. 747,384 shares of the company were exchanged. The stock’s 50-day moving average is $14.35 and its 200-day moving average is $14.14. Heron Therapeutics has a 12 month low of $12.21 and a 12 month high of $24.00.
Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings results on Wednesday, May 10th. The biotechnology company reported ($1.00) EPS for the quarter, missing the consensus estimate of ($0.94) by $0.06. The company had revenue of $3.63 million during the quarter, compared to analysts’ expectations of $1.96 million. Analysts predict that Heron Therapeutics will post ($3.70) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Cantor Fitzgerald Reiterates “Buy” Rating for Heron Therapeutics, Inc. (HRTX)” was first posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another publication, it was stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.com-unik.info/2017/06/16/heron-therapeutics-inc-hrtx-rating-reiterated-by-cantor-fitzgerald-updated-updated-updated.html.
In other Heron Therapeutics news, VP Kimberly Manhard sold 21,542 shares of the firm’s stock in a transaction on Monday, April 24th. The stock was sold at an average price of $15.33, for a total value of $330,238.86. Following the sale, the vice president now owns 5,250 shares of the company’s stock, valued at approximately $80,482.50. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 20.31% of the company’s stock.
Large investors have recently added to or reduced their stakes in the stock. Wells Fargo & Company MN increased its stake in Heron Therapeutics by 20.0% in the third quarter. Wells Fargo & Company MN now owns 11,167 shares of the biotechnology company’s stock valued at $192,000 after buying an additional 1,858 shares during the period. Partner Investment Management L.P. increased its stake in Heron Therapeutics by 16.5% in the third quarter. Partner Investment Management L.P. now owns 56,258 shares of the biotechnology company’s stock valued at $969,000 after buying an additional 7,979 shares during the period. Baker BROS. Advisors LP purchased a new stake in Heron Therapeutics during the third quarter valued at $49,230,000. Lombard Odier Asset Management USA Corp purchased a new stake in Heron Therapeutics during the third quarter valued at $3,015,000. Finally, RTW Investments LLC purchased a new stake in Heron Therapeutics during the third quarter valued at $6,664,000.
About Heron Therapeutics
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
What are top analysts saying about Heron Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Heron Therapeutics Inc. and related companies.